![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » AstraZeneca’s Tagrisso Nabs EU Approval for Early-Stage Lung Cancer
AstraZeneca’s Tagrisso Nabs EU Approval for Early-Stage Lung Cancer
![AstraZeneca](https://www.fdanews.com/ext/resources/test/Device_Images2/AstraZeneca.gif?t=1576126438&width=430)
The European Commission has authorized AstraZeneca’s blockbuster Tagrisso (osimertinib) as an adjuvant treatment for adult patients with early-stage epidermal growth-factor receptor-mutated nonsmall-cell lung cancer following complete tumor removal.
The approval was supported by results from a late-stage trial in which Tagrisso significantly improved disease-free survival by lowering the risk of disease recurrence by 80 percent.
Approved to treat early-stage lung cancer in more than 50 countries, Tagrisso earned $4.3 billion in global sales last year, an increase of 36 percent from the previous year.
Upcoming Events
-
21Oct